A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PADOVA
- Sponsors Roche
- 08 May 2024 According to a Prothena media release, topline results from Phase 2b PADOVA clinical trial in patients with early Parkinson's disease, which has completed enrollment, expected in 2H 2024.
- 02 Nov 2023 According to a Prothena media release, topline results expected in 2024.
- 07 Jul 2023 Status changed from recruiting to active, no longer recruiting.